menu
    • menu
    [{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Microbix Secures Funded Drug Commercialization Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Urokinase","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Microbix Biosystems","amount2":0.040000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Microbix Biosystems \/ Sequel Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Microbix B.."}]

    Find Clinical Drug Pipeline Developments & Deals for Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH2

    Menu

    Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH2

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Microbix Biosystems

                            Canada arrow
                            26th North American ISSX
                            Not Confirmed

                            Microbix Biosystems

                            Canada arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urokinase

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Sequel Pharma

                            Deal Size : $35.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Microbix Secures Funded Drug Commercialization Agreement

                            Details : The Agreement provides for Sequel to fund and undertake the necessary work to return Kinlytic (urokinase), a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture, to the U....

                            Product Name : Kinlytic

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 16, 2023

                            Lead Product(s) : Urokinase

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Sequel Pharma

                            Deal Size : $35.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth